Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Apr 7, 2011


Title: Methods and Compositions Involving microRNA

Patent Number: 7,919,245

Filed: Aug. 11, 2007

Lead Inventor: David Brown, Asuragen

The invention, the patent's abstract states, “concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules, and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the … invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.”

Title: Method for Expression of Small Antiviral RNA Molecules Within a Cell

Patent Number: 7,919,309

Filed: Sept.13, 2002

Lead Inventor: Carlos Lois-Cabelle, California Institute of Technology

“The invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector,” the patent's abstract states. “The methods can be used to express double-stranded RNA complexes. Small interfering RNA can be expressed using the methods of the invention within a cell [to] interfere with a viral life cycle by down-regulating either the viral genome, a viral genome transcript, or a host cell. … In another aspect, the invention provides methods for treating patients having suffering from infection, particularly infection with HIV.”

Title: iRNA Agents Targeting VEGF

Patent Number: 7,919,473

Filed: Jan. 25, 2006

Lead Inventor: Antonin De Fougerolles, Alnylam Pharmaceuticals

“The features of the ... invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor, such as by the mechanism of RNA interference,” according to the patent's abstract. “The compounds and compositions include iRNA agents that can be unmodified or chemically modified.”

Title: 2'-Substituted Oligomeric Compounds and Compositions for Use in Gene Modulation

Patent Number: 7,919,612

Filed: Nov. 4, 2003

Lead Inventor: Brenda Baker, Isis Pharmaceuticals

The patent, its abstract states, claims “compositions comprising [two] oligomers ... wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer; at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid; and at least one of the first or second oligomers includes a modified sugar and/or backbone modification.

“In some embodiments, the modification is a 2' substituent group on a sugar moiety that is not H or OH,” the abstract adds. “Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex, wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.”

Title: RNAi Modulation of SCAP and Therapeutic Uses Thereof

Patent Number: 7,919,613

Filed: March 29, 2010

Lead Inventor: Juergen Soutschek, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a SCAP gene comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19 [to] 25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene,” the patent's abstract states. “The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.”

Title: Novel Lipid Formulations for Delivery of Therapeutic Agents to Solid Tumors

Application Number: 20110076335

Filed: June 30, 2010

Lead Inventor: Ed Yaworski, Protiva Biotherapeutics (Tekmira Pharmaceuticals)

The invention, the patent application's abstract states, “provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the ... invention provides serum-stable nucleic acid-lipid particles comprising a nucleic acid, methods of making the [particles], and methods of delivering and/or administering the [particles]. In particular embodiments, the ... invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the ... invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.”

Title: Novel Methods for Quantification of microRNAs and Small Interfering RNAs

Application Number: 20110076675

Filed: June 1, 2009

Lead Inventor: Nana Jacobsen, Exiqon

“The invention relates to ribonucleic acids, probes, and methods for detection, quantification … [and] monitoring the expression of mature microRNAs and small interfering RNAs,” the patent application's abstract states. “The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts. ... The invention furthermore relates to methods for detection, quantification, [and] monitoring the expression of deoxy nucleic acids.”

Title: Modified Gene-Silencing Nucleic Acid Molecules and Uses Thereof

Application Number: 20110076681

Filed: March 31, 2010

Lead Inventor: Peter Michael Waterhouse, Commonwealth Scientific and Industrial Research Organization

The patent application, its abstract states, claims “methods and means for efficiently down-regulating the expression of a target gene of interest in cells from an organism that is an animal [and] fungus. ... The invention provides chimeric nucleic acid molecules for down-regulating target genes … [as well as] modified cells and organisms comprising the chimeric nucleic acid molecules and compositions comprising the chimeric molecules.”

Title: siRNA Targeting TIE-2

Application Number: 20110077173

Filed: Nov. 8, 2010

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.”

Title: Dry Powder Compositions for RNA Influenza Therapeutics

Application Number: 20110077284

Filed: Oct. 13, 2010

Lead Inventor: Luis Brito, Marina Biotech

The invention, the patent application's abstract states, comprises a “dry powder formulation for delivery to a mammal by inhalation [a] formulation comprising … a lipid, a carrier, and one or more double-stranded siRNA molecules or Dicer-active precursors targeted to influenza virus A, [which can be used as a] method for treating or preventing influenza in a mammal.”

Title: Oligonucleotide Duplexes Comprising DNA-Like and RNA-Like Nucleotides and Uses Thereof

Application Number: 20110077286

Filed: June 5, 2009

Lead Inventor: Masad Damha, McGill University

The invention, the patent application's abstract states, comprises “novel oligonucleotide pairs [that] can form a duplex comprising one or more DNA-like nucleotides in combination with one or more RNA-like nucleotides and/or locked nucleic acid nucleotides. ... The use of such oligonucleotide duplexes, such as for silencing the expression of a nucleic acid or gene of interest using small interfering RNA technologies, is also disclosed.”

Title: Method for Detecting Carcinoma and Agent for Suppressing Carcinoma

Application Number: 20110076768

Filed: Dec. 9, 2010

Lead Inventor: Johji Inazawa, Tokyo Medical and Dental University

The invention can be used to “identify genes exhibiting characteristic behavior in the cases of carcinoma such as oral squamous-cell carcinoma using a change of expression level of microRNA in oral squamous-cell carcinoma as an indicator, so as to provide a method for detecting carcinoma and an agent for suppressing carcinoma,” the patent application's abstract states. The invention comprises a “method for detecting oral squamous-cell carcinoma [by] detecting malignant transformation of specimens by employing a change of expression level of microRNA as an indicator, and an agent for suppressing oral squamous-cell carcinoma using microRNA.”

Title: Methods for Distinguishing Between Specific Types of Lung Cancers

Application Number: 20110077168

Filed: May 26, 2009

Lead Inventor: Nitzan Rosenfeld, Rosetta Genomics

The invention, the patent application's abstract states, “provides nucleic acid sequences that are used for identification, classification and diagnosis of lung cancers. The … invention further provides microRNA molecules, as well as various nucleic acid molecules relating thereto or derived therefrom, associated with specific types of lung cancers.”

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.